Virios Therapeutics, Inc. financial data

Symbol
VIRI on Nasdaq
Location
44 Milton Avenue, Alpharetta, GA
State of incorporation
DE
Fiscal year end
December 31
Former names
Virios Therapeutics, LLC (to 12/16/2020)
Latest financial report
10-Q - Q2 2024 - Aug 9, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 849 % +2.77%
Debt-to-equity 13.3 % -3.05%
Return On Equity -130 % -17%
Return On Assets -115 % -17.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27.8M shares +44.2%
Common Stock, Shares, Outstanding 27.8M shares +51.4%
Entity Public Float 24.4M USD -22%
Common Stock, Value, Issued 2.78K USD +49.2%
Weighted Average Number of Shares Outstanding, Basic 22.9M shares +24.4%
Weighted Average Number of Shares Outstanding, Diluted 22.9M shares +24.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.35M USD -65.8%
General and Administrative Expense 3.44M USD -8.57%
Operating Income (Loss) -4.8M USD +37.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -4.68M USD +38.3%
Net Income (Loss) Attributable to Parent -4.68M USD +38.3%
Earnings Per Share, Basic -0.24 USD/shares +31.4%
Earnings Per Share, Diluted -0.24 USD/shares +31.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 3.02M USD -34.2%
Assets, Current 3.64M USD -30.2%
Assets 3.64M USD -30.2%
Accounts Payable, Current 218K USD +1.61%
Employee-related Liabilities, Current 46.8K USD -82.1%
Accrued Liabilities, Current 282K USD -7.66%
Liabilities, Current 500K USD -3.84%
Deferred Income Tax Liabilities, Net 216K USD -36.7%
Liabilities 500K USD -3.84%
Retained Earnings (Accumulated Deficit) -63.8M USD -7.91%
Stockholders' Equity Attributable to Parent 3.14M USD -33.2%
Liabilities and Equity 3.64M USD -30.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -937K USD +44.8%
Common Stock, Shares Authorized 43M shares 0%
Common Stock, Shares, Issued 28M shares +48.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.02M USD -34.2%
Deferred Tax Assets, Valuation Allowance 9.93M USD +14.3%
Deferred Tax Assets, Gross 10.1M USD +12.4%
Deferred Tax Assets, Operating Loss Carryforwards 7.13M USD +25.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 2M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 67.2M USD +4.88%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 216K USD -36.7%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%